Author

Luis Bujanda Fernández de Piérola

DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
DIFFERENCES OF HELICOBACTER PYLORI DIAGNOSTICS AND TREATMENTS IN THE ELDERLY AND NON-ELDERLY POPULATIONS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
EMPIRICAL FIRST-LINE TREATMENT USE AND EFFECTIVENESS TRENDS IN EUROPE IN THE PERIOD 2013-2021: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EFFECTIVENESS AND SAFETY OF HIGH-DOSE DUAL THERAPY: RESULTS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

ADHERENCE TO FECAL IMMUNOCHEMICAL TESTS AND COLONOSCOPY IN FAMILIAL COLORECTAL CANCER SCREENING: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL
ADHERENCE TO FECAL IMMUNOCHEMICAL TESTS AND COLONOSCOPY IN FAMILIAL COLORECTAL CANCER SCREENING: A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL

Luis Bujanda Fernández de Piérola  et al.

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

Luis Bujanda Fernández de Piérola  et al.

EVALUATION OF THE ACCURACY OF THE "LIAISON(R) MERIDIAN HELICOBACTER PYLORI SA" STOOL ANTIGEN TEST FOR THE DIAGNOSIS OF H. PYLORI INFECTION: A SPANISH MULTICENTRE STUDY
EVALUATION OF THE ACCURACY OF THE "LIAISON(R) MERIDIAN HELICOBACTER PYLORI SA" STOOL ANTIGEN TEST FOR THE DIAGNOSIS OF H. PYLORI INFECTION: A SPANISH MULTICENTRE STUDY

Luis Bujanda Fernández de Piérola  et al.

REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
REAL-WORLD COMPARATIVE EFFECTS OF THREE-IN-ONE SINGLE CAPSULE BISMUTH QUADRUPLE THERAPY VS. NON-BISMUTH QUADRUPLE CONCOMITANT THERAPY: INTERIM ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

NOVEL PLATINUM-BASED CHEMOTHERAPEUTIC AGENTS HALT CHOLANGIOCARCINOMA PROGRESSION THROUGH THE INDUCTION OF DOUBLE-STRAND DNA BREAKS, PREVENTING DNA REPAIR MECHANISMS
NOVEL PLATINUM-BASED CHEMOTHERAPEUTIC AGENTS HALT CHOLANGIOCARCINOMA PROGRESSION THROUGH THE INDUCTION OF DOUBLE-STRAND DNA BREAKS, PREVENTING DNA REPAIR MECHANISMS

Luis Bujanda Fernández de Piérola  et al.

ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF COMPLIANCE IN HELICOBACTER PYLORI TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

SCAVENGER RECEPTOR MARCO IS ASSOCIATED WITH AN IMMUNOSUPPRESSIVE MICROENVIRONMENT AND TUMOR PROGRESSION IN INTRAHEPATIC CHOLANGIOCARCINOMA
SCAVENGER RECEPTOR MARCO IS ASSOCIATED WITH AN IMMUNOSUPPRESSIVE MICROENVIRONMENT AND TUMOR PROGRESSION IN INTRAHEPATIC CHOLANGIOCARCINOMA

Luis Bujanda Fernández de Piérola  et al.

PRESCRIPTION PATTERN OF PROBIOTICS AS AN ADJUVANT THERAPY FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
PRESCRIPTION PATTERN OF PROBIOTICS AS AN ADJUVANT THERAPY FOR HELICOBACTER PYLORI ERADICATION: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

IDENTIFICATION OF NEW GENES INVOLVED IN GERMLINE PREDISPOSITION TO EARLY-ONSET GASTRIC CANCER
IDENTIFICATION OF NEW GENES INVOLVED IN GERMLINE PREDISPOSITION TO EARLY-ONSET GASTRIC CANCER

Luis Bujanda Fernández de Piérola  et al.

IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
IMPACT OF PROBIOTICS USE ON THE SAFETY OF HELICOBACTER PYLORI TREATMENTS: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ERRORS IN EMPIRICAL ANTIBIOTIC THERAPIES FOR HELICOBACTER PYLORI ERADICATION IN 45,778 PATIENTS: DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

THERAPEUTIC POTENTIAL OF TARGETING PROTEIN HYPER-SUMOYLATION IN CHOLANGIOCARCINOMA
THERAPEUTIC POTENTIAL OF TARGETING PROTEIN HYPER-SUMOYLATION IN CHOLANGIOCARCINOMA

Luis Bujanda Fernández de Piérola  et al.

EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE
EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG): ANALYSIS OF EMPIRICAL SECOND-LINE TREATMENTS IN EUROPE

Luis Bujanda Fernández de Piérola  et al.

KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR
KLF5 UPREGULATION IS A COMMON EVENT IN CHOLANGIOCARCINOMA, ACTING AS AN ONCOGENE AND CONSTITUTING A BAD PROGNOSTIC FACTOR

Luis Bujanda Fernández de Piérola  et al.

LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
LONG-TERM EVOLUTION AFTER ANTI-TNF DRUG DISCONTINUATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Luis Bujanda Fernández de Piérola  et al.

BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
BISMUTH QUADRUPLE REGIMEN WITH TETRACYCLINE OR DOXYCYCLINE VERSUS PYLERA® AS THIRD-LINE RESCUE THERAPY FOR H. PYLORI INFECTION: A PROSPECTIVE MULTICENTER ANALYSIS OF THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

Luis Bujanda Fernández de Piérola  et al.

Item 21 - 40 / 50
1
2
3